Dr Bivek Kumar, Mch (URO.)
1.7K posts

Dr Bivek Kumar, Mch (URO.)
@BKidneydoc
drbivekkumar.urologist McH Uro.






Pure ethanol contains roughly 33% less energy/liter than pure petrol. When we move from E10 (10% ethanol) to E20/E30, we are essentially watering down the explosive power of our fuel with a liquid that packs a smaller punch. For E20, the real-world mileage drop ranges from 5% to 12%, depending on the engine's calibration. If the government pushes for E30, the drop is projected to hit 8% to 15% for vehicles not explicitly designed as "Flex-Fuel." To maintain the same speed & power, our car’s Engine Control Unit has to inject more fuel into the cylinder. Although, ethanol has a very high Octane Rating (~108). While Octane prevents knocking & allows for smoother acceleration, it does not equal mileage. Unless our engine has a High Compression Ratio (like a sports car/a specially tuned 2026 E20-tuned engine), that extra Octane is wasted. Most commuter bikes & budget cars in India cannot take advantage of the higher Octane to offset the lower energy density. We get a premium feel but a budget range.



Day 6 Update 🚨 Today I’m not traveling for my internship, I’m going for an art workshop 🎨 But nothing has changed. The road is still in the same condition. People are calling, asking for details… but on-ground action? Still zero. This clearly shows how seriously basic issues are taken. @MunCorpGurugram @DC_Gurugram @cmohry @HaryanaChief @PMOIndia @narendramodi @NHAI_Official














🚨 ASCO GU 2026 Top 15 Clinical Trials to Watch #GU26 🔵 Prostate Cancer |Precision & Intensification 🧪 CIPHER Testing platinum as a low-cost option in HRR-mutated mCRPC ☢️ PSMAaddition ¹⁷⁷Lu-PSMA-617 moves into mHSPC 🎯 PEACE-2 Systemic intensification (abiraterone + ADT) with definitive prostate RT 🔗 PEACE-3 Radioligand + ARPI combination in mCRPC 🧬 CAPItello-281 AKT pathway targeting in PTEN-deficient mHSPC 🟢 Bladder & Urothelial Cancer | ADCs & Bladder Preservation 🧬 KEYNOTE-B15 / EV-304 Perioperative EV + pembrolizumab as a new backbone in MIBC 🧪 VOLGA IO–ADC triplet strategy in perioperative MIBC 🫙 SunRISe-2 Bladder-sparing TAR-200 + cetrelimab in BCG-unresponsive NMIBC 🧫 Disitamab vedotin + pembrolizumab ADC expansion beyond enfortumab in HER2-expressing disease 🩸 RETAIN trials (LBA632) ctDNA-guided, response-adapted bladder preservation in MIBC 🟡 Renal Cell Carcinoma | Post-IO Sequencing 🧪 LITESPARK-011 Belzutifan combinations after IO–TKI failure 🛡️ LITESPARK-022 HIF-2α inhibition enters the adjuvant setting 🔁 TiNivo-2 IO rechallenge tested rigorously 💊 STELLAR-001 Next-generation TKI (XL092) strategies 🔪 CYTOSHRINK Response-adapted cytoreductive nephrectomy after systemic therapy #ASCOGU26 #GUOncology #OncoTwitter #MedTwitter @OncoAlert @myesmo @esmo_open @asco @Larvol






